Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancer.
Dietz S, Christopoulos P, Gu L, Volckmar AL, Endris V, Yuan Z, Ogrodnik SJ, Zemojtel T, Heussel CP, Schneider MA, Meister M, Muley T, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. Dietz S, et al. Among authors: reck m. Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6):a004630. doi: 10.1101/mcs.a004630. Print 2019 Dec. Cold Spring Harb Mol Case Stud. 2019. PMID: 31753813 Free PMC article.
[Treatment of non-small cell lung cancer].
Reinmuth N, Heigener D, Reck M. Reinmuth N, et al. Among authors: reck m. Internist (Berl). 2011 Dec;52(12):1414-21. doi: 10.1007/s00108-011-2925-1. Internist (Berl). 2011. PMID: 22095048 Review. German.
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M. Heigener DF, et al. Among authors: reck m. Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3. Lung Cancer. 2014. PMID: 24560332 Clinical Trial.
Crizotinib.
Heigener DF, Reck M. Heigener DF, et al. Among authors: reck m. Recent Results Cancer Res. 2014;201:197-205. doi: 10.1007/978-3-642-54490-3_11. Recent Results Cancer Res. 2014. PMID: 24756793 Review.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Garon EB, et al. Among authors: reck m. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2. Lancet. 2014. PMID: 24933332 Clinical Trial.
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Ramlau R, Thomas M, Novello S, Plummer R, Reck M, Kaneko T, Lau MR, Margetts J, Lunec J, Nutt J, Scagliotti GV. Ramlau R, et al. Among authors: reck m. Clin Lung Cancer. 2015 Sep;16(5):348-57. doi: 10.1016/j.cllc.2015.01.004. Epub 2015 Jan 20. Clin Lung Cancer. 2015. PMID: 25700774 Free article. Clinical Trial.
Targeting of MEK in lung cancer therapeutics.
Heigener DF, Gandara DR, Reck M. Heigener DF, et al. Among authors: reck m. Lancet Respir Med. 2015 Apr;3(4):319-27. doi: 10.1016/S2213-2600(15)00026-0. Epub 2015 Mar 20. Lancet Respir Med. 2015. PMID: 25801412 Review.
520 results